New device zaps nerves to tame high blood pressure

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Subject with age ≥18 years or minimum age as required by local regulations and ≤ 70 years old at time of consent 2. Subject with hypertension who has an office BP of ≥ 150/90 mmHg and \< 180/110 mmHg (meet both SBP and DBP criteria) at Screening V2, and mean daytime ASBP ≥ 140 mmHg and \< 170 mmHg by 24-hour ABPM at Screening V2. 3. Willing and able to provide informed consent 4. Willing and able to comply with all study-specific visits, assessments, and requirements Exclusion Criteria: 1. 1\. Subject who is pregnant, nursing or planning to become pregnant during the course of the study 2. Subject with unilateral or bilateral renal artery that are not suitable for ablation procedure (renal artery stenosis more than 50%, renal aneurysm, renal artery abnormality, renal artery diameter \< 3 mm or treatable segment length \< 20 mm) 3. Subject with single-kidney or history of kidney transplant 4. Subject with history of renal artery intervention (Percutaneous Transluminal Angioplasty \[PTA\] or stenting) or Renal Denervation (RDN) 5. Subject with any conditions that may affect the accuracy of blood pressure (BP) measurement: such as the diameter of the upper arm is too large for the cuff, or arrhythmia, etc 6. Subject with known secondary hypertension 7. Subject with eGFR \<40 mL/min/l.73m² 8. Subject with history of hospitalization for hypertensive emergency within past year 9. Subject with type I diabetes mellitus 10. Subject with primary pulmonary hypertension 11. Subject with history of bleeding diathesis and haematological disorders or coagulopathy 12. Subject with recent history of any embolism within 6 months 13. Subject with history of coronary artery intervention, unstable angina or myocardial infarction 14. Subject with stable angina and therefore treated anti-anginal medication (betablockers, calcium antagonists, long-acting nitrates) 15. Subject with history of abdominal aortic aneurysm 16. Subject with atrial fibrillation or history of atrial fibrillation in the last 3 years or on rate or rhythm control medication for arrhythmia 17. Subject with a history of ventricular fibrillation or ventricular tachycardia 18. Subject known with serum Human Immunodeficiency Virus (HIV)-positive 19. Subject who is allergic to contrast agents and not responding to preventive medication 20. Subject with acute or severe systemic infections 21. Subject with mental illness or any psychological problems that may interfere with participating in the study 22. Subject with history of stroke or transient ischemic attack (TIA) 23. Subject with malignant tumors or end-stage disease 24. Subject with severe Peripheral Artery Disease (PAD) along the access path to renal arteries, including abdominal aneurysm 25. Subject with severe heart valve stenosis or regurgitation 26. Subject with heart failure requiring medications (i.e. Angiotensin-Converting Enzyme (ACE)/ Angiotensin II Receptor Blockers (ARB), Sodium-Glucose Cotransporter 2 Inhibitors (SGTL2i), diuretics) 27. Subject with uncontrolled hyperthyroidism or hypothyroidism 28. Subject with severe electrolyte abnormalities, defined as values above and below the limits of normal (LN) on repeated measurements despite normalization efforts, or with liver function abnormalities, defined as 2 \> Upper Limit of Normal (ULN) 29. Subject who requires mechanical ventilation other than Continuous Positive Airway Pressure (CPAP) for sleep apnea 30. Subject with an implanted pacemaker or Implantable Cardioverter Defibrillator (ICD)/ Cardiac Resynchronization Therapy (CRT) device 31. Subject with a history of major surgery or trauma within 30 days prior to enrolment 32. Subject who has planned surgery or cardiovascular intervention within the next 12 months 33. Subject who is participating in other drug or medical device clinical investigations 34. Subject who is unsuitable to participate in this study in the opinion of investigators (e.g., drug use or alcohol dependency, cognitive impairment, etc.)